These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease. Labetoulle M; Garhöfer G; Ismail D; Garrigue JS; Amrane M; Guillon M; Aragona P; Baudouin C Acta Ophthalmol; 2024 Jun; 102(4):382-390. PubMed ID: 38294079 [TBL] [Abstract][Full Text] [Related]
23. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. Craig JP; Muntz A; Wang MTM; Luensmann D; Tan J; Trave Huarte S; Xue AL; Jones L; Willcox MDP; Wolffsohn JS Ocul Surf; 2021 Apr; 20():62-69. PubMed ID: 33401019 [TBL] [Abstract][Full Text] [Related]
24. Effects of Menthol-Containing Artificial Tears on Tear Stimulation and Ocular Surface Integrity in Normal and Dry Eye Rat Models. Ahn S; Eom Y; Kang B; Park J; Lee HK; Kim HM; Song JS Curr Eye Res; 2018 May; 43(5):580-587. PubMed ID: 29419317 [TBL] [Abstract][Full Text] [Related]
25. The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. Balal S; Udoh A; Pappas Y; Cook E; Barton G; Hassan A; Hayden K; Bourne RRA; Ahmad S; Pardhan S; Harrison M; Sharma B; Wasil M; Sharma A BMJ Open; 2018 Oct; 8(10):e026770. PubMed ID: 30385451 [TBL] [Abstract][Full Text] [Related]
26. Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis. Gulati S; Jain S Handb Exp Pharmacol; 2017; 242():97-118. PubMed ID: 27913889 [TBL] [Abstract][Full Text] [Related]
27. Dry Eye Management: Targeting the Ocular Surface Microenvironment. Zhang X; M VJ; Qu Y; He X; Ou S; Bu J; Jia C; Wang J; Wu H; Liu Z; Li W Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28661456 [TBL] [Abstract][Full Text] [Related]
28. A comparison between hyaluronic acid and other single ingredient eye drops for dry eye, a review. Hynnekleiv L; Magno M; Moschowits E; Tønseth KA; Vehof J; Utheim TP Acta Ophthalmol; 2024 Feb; 102(1):25-37. PubMed ID: 37042308 [TBL] [Abstract][Full Text] [Related]
29. Effect of artificial tears on dynamic optical quality in patients with dry eye disease. Wei Z; Su Y; Su G; Baudouin C; Labbé A; Liang Q BMC Ophthalmol; 2022 Feb; 22(1):64. PubMed ID: 35144571 [TBL] [Abstract][Full Text] [Related]
30. An Oral Polyphenol Formulation to Modulate the Ocular Surface Inflammatory Process and to Improve the Symptomatology Associated with Dry Eye Disease. Ng D; Altamirano-Vallejo JC; Gonzalez-De la Rosa A; Navarro-Partida J; Valdez-Garcia JE; Acosta-Gonzalez R; Martinez Camarillo JC; Bustamante-Arias A; Armendariz-Borunda J; Santos A Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956412 [TBL] [Abstract][Full Text] [Related]
31. Propylene Glycol and Hydroxypropyl Guar Nanoemulsion - Safe and Effective Lubricant Eye Drops in the Management of Dry Eye Disease. Srinivasan S; Williams R Clin Ophthalmol; 2022; 16():3311-3326. PubMed ID: 36237486 [TBL] [Abstract][Full Text] [Related]
32. Viscoelastic properties of the human tear film. Recchioni A; Mocciardini E; Ponzini E; Tavazzi S Exp Eye Res; 2022 Jun; 219():109083. PubMed ID: 35460666 [TBL] [Abstract][Full Text] [Related]
33. Influence of Artificial Tears on Keratometric Measurements in Cataract Patients. Röggla V; Leydolt C; Schartmüller D; Schwarzenbacher L; Meyer E; Abela-Formanek C; Menapace R Am J Ophthalmol; 2021 Jan; 221():1-8. PubMed ID: 32828877 [TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956 [TBL] [Abstract][Full Text] [Related]
35. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103 [TBL] [Abstract][Full Text] [Related]
36. Synergistic Effect of Artificial Tears Containing Epigallocatechin Gallate and Hyaluronic Acid for the Treatment of Rabbits with Dry Eye Syndrome. Tseng CL; Hung YJ; Chen ZY; Fang HW; Chen KH PLoS One; 2016; 11(6):e0157982. PubMed ID: 27336157 [TBL] [Abstract][Full Text] [Related]
37. The Importance of Preventing and Managing Tear Dysfunction Syndrome in Allergic Conjunctivitis and How to Tackle This Problem. Montero-Iruzubieta J; Sanchez Hernandez MC; Dávila I; Leceta A J Investig Allergol Clin Immunol; 2023 Dec; 33(6):439-445. PubMed ID: 38095493 [TBL] [Abstract][Full Text] [Related]
38. Cross-Linked Hyaluronic Acid as Tear Film Substitute. Posarelli C; Passani A; Del Re M; Fogli S; Toro MD; Ferreras A; Figus M J Ocul Pharmacol Ther; 2019 Sep; 35(7):381-387. PubMed ID: 31373862 [No Abstract] [Full Text] [Related]
39. The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model. Guarise C; Acquasaliente L; Pasut G; Pavan M; Soato M; Garofolin G; Beninatto R; Giacomel E; Sartori E; Galesso D J Mech Behav Biomed Mater; 2023 Jul; 143():105908. PubMed ID: 37209594 [TBL] [Abstract][Full Text] [Related]
40. The efficacy of ocular surface assessment approaches in evaluating dry eye treatment with artificial tears. Szczesna-Iskander DH; Muzyka-Wozniak M; Llorens Quintana C Sci Rep; 2022 Dec; 12(1):21835. PubMed ID: 36528723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]